Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an announcement.
Australian Clinical Labs has provided an updated notification to the ASX on its ongoing on-market share buy-back of ordinary fully paid shares. The latest daily report, dated 18 March 2026, confirms that the company repurchased 80,063 shares in the previous trading day, bringing the total number of shares bought back under the program to 5,923,429.
The continued execution of the on-market buy-back signals management’s commitment to capital management and returning value to shareholders. By reducing the number of shares on issue through regular market purchases, Australian Clinical Labs may enhance earnings per share and support its share price, with implications for investor perception of the company’s financial strength and confidence in its long-term outlook.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is an Australian pathology services provider listed on the ASX under the code ACL. The company operates in the healthcare diagnostics sector, offering laboratory testing services and related clinical support across its network to healthcare providers and patients.
Average Trading Volume: 701,513
Technical Sentiment Signal: Sell
Current Market Cap: A$384.4M
Find detailed analytics on ACL stock on TipRanks’ Stock Analysis page.